

SEP 12 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/773,772	
	Filing Date	February 06, 2004	
	First Named Inventor	Martin MICHAELIS et al.	
	Art Unit	1654	
	Examiner Name	CORDERO GARCIA, Marcela M.	
Total Number of Pages in This Submission	3	Attorney Docket Number	DEAV2003/0008 US NP

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; height: 40px; width: 100%;"></div>
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Joseph D. Rossi		
Date	September 12, 2005	Reg. No.	47,038

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 : Total No. of Pages Transmitted: 3)			
Signature			
Typed or printed name	Paul Irvine	Date	September 12, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP. 12. 2005 2:36PM AVENTIS US PAT DEPT
DEAV2003/0008 US NP

RECEIVED
CENTRAL FAX CENTER

NO. 8125 P. 2
PATENT

SEP 12 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Michaelis, et al.

Examiner: M. CORDERO GARCIA

Art Unit: 1654

Serial No.: 10/773,772

Filed: February 6, 2004

Title: **THE USE OF ANTAGONISTS OF THE
BRADYKININ B2 RECEPTOR FOR THE
TREATMENT OF OSTEOARTHRISIS**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on

September 12, 2005

Date of Deposit

Signature

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement, dated August 12, 2005, Applicants submit as follows:

Applicants elect for prosecution on the merits, with traverse, the compound according to claim 5 wherein the compound of formula I is D-arginyl-L-arginyl-L-prolyl-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-L-arginine.


Applicants reserve the right to pursue the non-elected subject matter in one or more divisional applications prior to issuance of a patent on the instance application.

Any additional fees or charges required at this time in connection with the above-identified patent application may be charged to our Patent and Trademark Office Deposit Account No. 18-1982.

Respectfully submitted,

September 12, 2005

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626


Joseph D. Rossi, Reg. No. 47,038
Attorney for Applicant

Docket No. DEAV2003/0008 US NP